ImmuneOnco Biopharmaceuticals (Shanghai) (HKSE:01541) Margin of Safety % (DCF Earnings Based): N/A (As of Aug. 12, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:01541 ImmuneOnco Biopharmaceuticals (Shanghai) Inc HKSE:01541
6 GF Score
Price HK$3.72
! 5 Warning Signs
View Full Analysis

What is ImmuneOnco Biopharmaceuticals (Shanghai) Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

ImmuneOnco Biopharmaceuticals (Shanghai)'s Predictability Rank is Not Rated. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

HKSE:01541 vs VRTX, REGN, RVMD: Margin of Safety % (DCF Earnings Based) Comparison

For the Biotechnology subindustry, ImmuneOnco Biopharmaceuticals (Shanghai)'s Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ImmuneOnco Biopharmaceuticals (Shanghai) Margin of Safety % (DCF Earnings Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ImmuneOnco Biopharmaceuticals (Shanghai)'s Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where ImmuneOnco Biopharmaceuticals (Shanghai)'s Margin of Safety % (DCF Earnings Based) falls into.


HKSE:01541
6GF Score
ImmuneOnco Biopharmaceuticals (Shanghai) Inc HKSE:01541
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ImmuneOnco Biopharmaceuticals (Shanghai) Business Description

Address 1000 Zhangheng Road, Unit 15, China (Shanghai) Pilot Free Trade Zone, Pudong New Area, Shanghai, CHN
ImmuneOnco Biopharmaceuticals (Shanghai) Inc is a science-driven biotechnology company dedicated to the development of immuno-oncology therapies. It is one of the few biotechnology companies globally adopting a systematic approach to harness both the innate and adaptive immune systems. It has designed a robust pipeline of over ten drug candidates with 12 ongoing clinical programs., featured by a comprehensive innate-immunity-based asset portfolio. Its pipeline reflects its extensive understanding of the frontiers of cancer biology and immunology and its expertise in turning scientific research into drug candidates.
6GF Score

Get the complete analysis for HKSE:01541

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$3.72
Price